Products for Research Use Only

Cilastatin-15N, d3

CAT: 0804-HY-A0166SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-A0166SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cilastatin-15N, d3 is a 15N-labeled and deuterium labeled Cilastatin. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct[1][2][3].
CAS Number
2738376-83-3
Product Name Alternative
MK0791-15N, d3
UNSPSC
12352211
Target
Antibiotic; Bacterial
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Purity
99.71
Solubility
1 M NaOH : 100mg/mL (ultrasonic; adjust pH to 12 with NaOH) |10 mM in DMSO|DMSO : 100mg/mL (ultrasonic) |H2O : 12.5mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(O)/C(NC([C@@H]1C(C)(C)C1)=O)=C/CCCCSC([2H])([2H])C([15NH2])([2H])C(O)=O
Molecular Formula
C16H23D3N 15NO5S
Molecular Weight
362.46
References & Citations
[4]The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterialmetallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39 (7) :1629-31.|[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Blanca Humanes, et al. Protective Effects of Cilastatin Against Vancomycin-Induced Nephrotoxicity. Biomed Res Int. 2015;2015:704382.|[3]P J Petersen, et al. In Vitro and in Vivo Activities of LJC10,627, a New Carbapenem With Stability to Dehydropeptidase I. Antimicrob Agents Chemother. 1991 Jan;35 (1) :203-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
β-lactam